PARP Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

PARP Inhibitors: What Do We know?

PARP Inhibitors: What Do We Know? (cont)

PARP Inhibitors: What Don't We Know ?

SOLO-1: Study Rationale and Design[a]

Primary Endpoint and Other Results

Time to Second Progression or Death (PFS2)

SOLO-1 Conclusions

PAOLA-1: Phase 3 Trial of Olaparib Plus Bevacizumab vs Placebo Plus Bevacizumab as Maintenance Treatment in Advanced Ovarian Cancer

VELIA: Phase 3 Trial of Veliparib With Carboplatin and Paclitaxel as Continuous Maintenance

PRIMA: Phase 3 Trial of Niraparib vs Placebo as Maintenance Treatment in Advanced Ovarian Cancer

PARP Inhibitors as Maintenance Therapy

QUADRA

Updated Analysis of QUADRA

ORR in Biomarker-Defined, Response-Evaluable Population

Strategies for the Future

Randomized Phase 2 Trial Combining Cediranib and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

Phase 3 NCI GY004 PFS by BRCA Status

NCI GY004 (Platinum Sensitive)

NCI GY005 (COCOS/Platinum Resistant)

ICON9: Randomized Trial of Cediranib and Olaparib Maintenance in Relapsed Platinum-Sensitive Ovarian Cancer

MEDIOLA: Phase 2 Basket Study of Olaparib + PDL1 Antibody (Durvalumab) in BRCAm-Positive Relapsed Ovarian Cancer

TOPACIO: Single-Arm Trial of PARP Inhibitor (Niraparib) + Anti-PDL1 (Pembrolizumab)

JAVELIN Ovarian 100 PARP

ATHENA Study Design

Which First-Line Trials Are Enrolling Patients?

Take-Home Messages

Take-Home Messages (cont)

Take-Home Messages (cont)

Abbreviations

Abbreviations (cont)